CD8A and melanoma: Indeed, recent data suggest that BRAF-targeted therapy may foster host immune responses to melanoma, characterised by enhanced expression of melanoma differentiation antigens, reduced levels of immunosuppressive cytokines in the microenvironment, a CD8 T-cell response and T-cell-mediated cytotoxicity [41].